{
    "clinical_study": {
        "@rank": "36818", 
        "arm_group": [
            {
                "arm_group_label": "Stage 1: Bimatoprost Solution 1", 
                "arm_group_type": "Experimental", 
                "description": "Stage 1: Bimatoprost Solution 1 applied evenly onto pre-specified area on scalp daily for 28 days."
            }, 
            {
                "arm_group_label": "Stage 2: Bimatoprost Solution 1", 
                "arm_group_type": "Experimental", 
                "description": "Stage 2: Bimatoprost Solution 1 applied evenly onto pre-specified area on scalp daily for 6 months."
            }, 
            {
                "arm_group_label": "Stage 1: Bimatoprost Solution 2", 
                "arm_group_type": "Experimental", 
                "description": "Stage 1: Bimatoprost Solution 2 applied evenly onto pre-specified area on scalp daily for 28 days."
            }, 
            {
                "arm_group_label": "Stage 2: Bimatoprost Solution 2", 
                "arm_group_type": "Experimental", 
                "description": "Stage 2: Bimatoprost Solution 2 applied evenly onto pre-specified area on scalp daily for 6 months."
            }, 
            {
                "arm_group_label": "Stage 1: Bimatoprost Vehicle", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Stage 1: Bimatoprost Vehicle (placebo) applied evenly onto pre-specified area on scalp daily for 28 days."
            }, 
            {
                "arm_group_label": "Stage 2: Bimatoprost Vehicle", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Stage 2: Bimatoprost Vehicle (placebo) applied evenly onto pre-specified area on scalp daily for 6 months."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a safety and efficacy study of bimatoprost in male subjects with androgenic alopecia\n      (AGA)."
        }, 
        "brief_title": "A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Alopecia", 
            "Alopecia, Androgenetic", 
            "Baldness"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Alopecia", 
                "Alopecia Areata"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Mild to moderate male pattern baldness (androgenic alopecia) with ongoing hair loss\n             for at least 1 year\n\n          -  Willingness to maintain same hair style, length and hair color during study\n\n          -  Willingness to have micro-dot-tattoo applied to scalp  (Stage 2 only)\n\n        Exclusion Criteria:\n\n          -  Drug or alcohol abuse within 12 months\n\n          -  HIV positive\n\n          -  Received hair transplants or had scalp reductions\n\n          -  Use of hair weaves, hair extensions or wigs within 3 months\n\n          -  Use of minoxidil (oral or topical) and/or low level light treatment \"combs\" for hair\n             growth within the last 6 months, or expected use during the study\n\n          -  Application of topical steroids or nonsteroidal anti-inflammatory drugs (NSAIDs) to\n             scalp within 4 weeks"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "49 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "246", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01904721", 
            "org_study_id": "192024-084"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Stage 1: Bimatoprost Solution 1", 
                    "Stage 2: Bimatoprost Solution 1"
                ], 
                "description": "Bimatoprost Solution 1 applied evenly onto pre-specified area on scalp daily for 28 days, or daily for 6 months.", 
                "intervention_name": "Bimatoprost Solution 1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Stage 1: Bimatoprost Solution 2", 
                    "Stage 2: Bimatoprost Solution 2"
                ], 
                "description": "Bimatoprost Solution 2 applied evenly onto pre-specified area on scalp daily for 28 days, or daily for 6 months.", 
                "intervention_name": "Bimatoprost Solution 2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Stage 1: Bimatoprost Vehicle", 
                    "Stage 2: Bimatoprost Vehicle"
                ], 
                "description": "Bimatoprost Vehicle (placebo) applied evenly onto pre-specified area on scalp daily for 28 days, or daily for 6 months.", 
                "intervention_name": "Bimatoprost Vehicle", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bimatoprost", 
                "Cloprostenol"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 21, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fridley", 
                    "country": "United States", 
                    "state": "Minnesota"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from Baseline in Target Area Hair Count (TAHC)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Month 6"
            }, 
            {
                "measure": "Subject Self Assessment in Alopecia (SSA) Score on a 7-Point Scale", 
                "safety_issue": "No", 
                "time_frame": "Month 6"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01904721"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Investigator Global Assessment (IGA) Score on a 7-Point Scale", 
                "safety_issue": "No", 
                "time_frame": "Month 6"
            }, 
            {
                "measure": "Global Panel Review (GPR) Score on a 7-Point Scale", 
                "safety_issue": "No", 
                "time_frame": "Month 6"
            }, 
            {
                "measure": "Change from Baseline in Target Area Hair Width (TAHW)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Month 6"
            }, 
            {
                "measure": "Change from Baseline in Target Area Hair Darkness (TAHD)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Month 6"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}